Stipple Bio, Inc.
Biotechnology · Cambridge, MA
BiotechnologySEC Form D
Stipple Bio, Inc. filed a Form D with the U.S. Securities and Exchange Commission on April 6, 2026, reporting $65,130,013 raised toward a $100,200,007 offering.
Incorporated in Delaware and based in Cambridge, MA, it operates in the Biotechnology sector.
Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that Stipple Bio, Inc. has raised capital from private investors.
Browse more recently funded companies in Biotechnology.
Executives & Directors
- Jeffrey LandauExecutive Officer · Director
- Vineeta AgarwalaDirector
- Owen HughesDirector
- Greg VerdineDirector
- Aaron RingDirector
- Derek DiRoccoDirector
- Thilo SchroederDirector
Recently funded in Biotechnology
Other companies that recently filed a Form D
$3.2MRaised
Goldenrod Therapeutics, Inc.
$10.0MRaised
Human Biotech, Inc.
$1.0MRaised
Optimeos Life Sciences, Inc.
$2.5MRaised
BioStem Technologies, Inc.
$10.0MRaised